Preclinical

PRECLINICAL ARTICLES

iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody
iBio has started clinical trials with a long-acting myostatin/GDF11 antibody that can make weight loss healthier and more durable for patients taking GLP-1 agonists.
The Future Is Ancient: Evolution, Metabolics, And AI
We caught up with Hannah Gordon, Ph.D., chief scientific officer of Enveda, to discuss why the future may depend more on decoding nature’s evolutionarily selected chemistry.
Beyond Engineered Antibodies: Harnessing The Natural Human Repertoire
We caught up Srikanth Pendyala, MD, CMO of Infinimmune, to discuss the importance of learning directly from the human immune system itself in antibody research.
Aligning Standards, Validation, And Governance For Digital Preclinical Research
No single body integrates preclinical data components into a coherent discipline supported by shared standards, common terminology, and collective accountability.
2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio
Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.
2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore
Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development.

PRECLINICAL VIDEOS

Audience Poll: Validation and Trust Are Biggests Barriers to Organ on Chip Adoption

Validation And Trust Are The Biggest Barriers To Organ On Chip Adoption

In a live audience poll, 46% of respondents cited validation and trust as the biggest barriers to broader organ‑on‑chip adoption. The result suggests the technology itself is no longer the main hurdle; instead, confidence in reproducibility, benchmarking, and fit‑for‑purpose use will determine how quickly these models are integrated into drug discovery decision‑making.

Why Women's Health Is A Breakthrough Use Case For Organ Chips

Women’s health research highlights both the limitations of traditional models and the strengths of organ‑on‑chip systems. Panelists describe how hormone dynamics, immune signaling, microbiomes, and sex‑specific biology can be studied with unprecedented precision, enabling mechanistic insights that were previously inaccessible and opening new paths beyond symptom‑based treatment.

Where Organ On Chips Will Add The Most Value In 3–5 Years

Panelists emphasized that CROs and CDMOs will be essential to scaling organ on chip adoption, but only if they commit to standardized, commercial execution rather than treating these systems as experimental add ons. As Don Ingber put it plainly, CROs “need to start buying these commercial systems and start scaling” them to make organ on chip studies operationally viable for industry.

The Reality Of Human On A Chip Systems

Whole‑body human‑on‑chip platforms are technically feasible, but panelists caution against viewing them as near‑term solutions for drug development. Instead, progress is being driven by strategically linked organ systems designed to answer specific biological questions—often supported by computational modeling to manage complexity.

PRECLINICAL ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

LNP-Mediated Cell Transfection In Bioreactors Across Workflows

Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.
Towards A Universal LNP Platform For Multiplex Engineering

Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
Extrahepatic Delivery Of mRNA-LNP To Spleen

In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.
The History Of Chemical Nomenclature And ACD/Name

Modern chemical naming requires algorithmic precision to match evolving standards and new compound classes. Up-to-date nomenclature ensures regulatory compliance and seamless workflow integration.
What DEL-Derived Hits Reveal About Library Design

Balanced chemical properties drive more efficient optimization and reduce risk. Discover how chemistry-driven library design consistently produces more tractable compounds, improving SAR productivity.
High Content Imaging

Learn how high-content imaging enables deeper cellular insights, accelerates hit-to-lead progression, and enhances decision-making through multiparametric analysis.
Workflow For Chemical Characterization And Database Curation

Confident identification of known and unknown compounds starts with smarter LC/MS and GC/MS workflows. Learn how structure elucidation, verification, and centralized data curation work together.
Improving pKa Prediction Accuracy For PROTACs

Gain insight into how localized modeling of ionizable centers, supported by curated experimental data, delivers reliable predictions that strengthen physicochemical decision-making.
Property-Based Optimization Of Pharmaceutical Lead Compounds

Property-driven optimization helps medicinal chemists focus synthetic effort where it matters most. See how integrating ADME and physicochemical predictions can surface better-balanced lead candidates.
Deepening Digitalization In Drug Discovery At PTC Therapeutics

Digital integration of physicochemical property prediction transforms how chemists evaluate compounds, enabling faster analysis, stronger structure, and more informed decisions across libraries.
The Future Of DMTA In Drug Discovery And Development

AI‑enabled DMTA cycles connect design, experimentation, and analysis through structured data and automation, reducing manual handoffs while accelerating discovery, development, and CMC decision‑making.
Integrated Drug Discovery: Hit To PCC In 16 Months

Accelerate your drug discovery program with integrated, cross-functional expertise that advances promising candidates from hit identification to preclinical development with speed and efficiency.

PRECLINICAL SOLUTIONS

Streamline High Throughput Experimentation And Process Development

Software for Automated, Digitalized Experimentation

Katalyst D2D® (Design-to-Decide) provides integrated experiment design, planning, execution, and analysis for high-throughput synthesis, process optimization, and preformulation studies. It helps scientists execute experiments more efficiently and connect data with decisions across the design-make-test-analyze (DMTA) cycle.
Clean Blood And Tissue DNA Kit

Magnetic bead-based genomic DNA extraction kit.
Pipetting Robot For Full Workflow Automation

Frees you from routine pipetting and provides excellent results
Streamlining Magnetic Bead Purifications

We have introduced the MAG and HEATMAG modules with you, the scientists, in mind.
Magnetic Beads For NGS Size Selection And PCR Purification

MAGFLO magnetic beads are only available in Austria, Belgium, Denmark, France, Germany, Ireland, Netherlands, Sweden, Switzerland and the United Kingdom.
Small Molecule Exponential Discovery

Explore how a data‑driven discovery model combines DEL screening, computational insights, and medicinal chemistry to accelerate hit‑to‑lead decisions, reduce risk, and enable efficient progression.
Turning Screening Data Into Discovery Direction

Chemomics transforms full DEL datasets into predictive insights. See how combining large-scale screening with clear computational models accelerates SAR understanding and strengthens confidence.
An Organ-Chip Platform That Generates Human-Relevant Data At Scale

Generate human-relevant data with an Organ-Chip system that combines automation, imaging, and cost efficiency for faster, more confident insights for drug development and complex biological studies.
A Revolutionary Consumable Empowering High-Throughput Organ-Chip Studies

With 12 independent Emulations in one consumable, Chip-Array optimizes workflows and reduces cell requirements—delivering scalable, physiologically relevant models for advanced research.
Complete Organ-Chip Solutions To Fast-Track Your Drug Discovery

From cancer models to high-throughput screening, Organ-Chip platforms accelerate development, improve safety, and support regulatory compliance for next-generation therapies.
A Human-Relevant Liver Model With Minimal Drug Absorption

This human-relevant liver model featuring a rigid plastic is designed to minimize small-molecule drug absorption. Explore the specifications of this product engineered to model the liver.

PRECLINICAL ARTICLES

PRECLINICAL VIDEOS

PRECLINICAL ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

Newsletter Signup

PRECLINICAL SOLUTIONS